Navigation Links
Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
Date:4/8/2013

PegIFN/RBV. Three additional STARTVerso™ trials in treatment-naïve, treatment-experienced and HIV co-infected patients with chronic genotype-1 HCV are near clinical completion. BI 207127 is an investigational NS5B non-nucleoside polymerase inhibitor that has shown the potential to eliminate interferon from HCV treatment when combined in a regimen with faldaprevir and RBV. Phase 2 trials of this interferon-free regimen have been completed and Phase 3 HCVerso™ trials are now underway. As part of our long-term commitment to HCV, the company is exploring other combinations of investigational HCV compounds that work in different ways. The recent collaboration of Boehringer Ingelheim with Presidio Pharmaceuticals, Inc. for a Phase 2 clinical study investigating an interferon-free, all-oral combination is part of the company's continued commitment to discover and develop innovative options for the treatment of HCV.

Faldaprevir and BI 207127 are investigational compounds and not approved by the FDA. Their safety and efficacy have not been established.

Hepatitis C is a blood-born infectious disease and a leading cause of chronic liver disease, transplant and failure that affects as many as 150 million people globally. In the United States, an estimated 4.1 million Americans have been infected with HCV, of which approximately 3.2 million have chronic HCV infection. Since 1999 there has been a significant increase in deaths due to chronic HCV, accounting for 15,000 deaths in the United States in 2007.

About Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading phar
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. European Medicines Agency accepts marketing authorization application for Boehringer Ingelheim and Eli Lilly and Companys empagliflozin*, an investigational type 2 diabetes treatment
2. Boehringer Ingelheim and Eli Lilly and Company submit new drug application to FDA for empagliflozin, an investigational type 2 diabetes treatment
3. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
4. Boehringer Ingelheim Cares Foundation Launches Online Giving Report
5. Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status
6. Pharmaceutical Leader Boehringer Ingelheim Selects Republica as Cross-Cultural Marketing Agency
7. Boehringer Ingelheim Selects ChemAxon to Power Next-Generation Global Cheminformatics Platform
8. FDA Advisory Committee Recommends Approval for Boehringer Ingelheims Olodaterol for Maintenance Treatment of COPD
9. Boehringer Ingelheim and Ashoka Changemakers Launch Competition to Find Business Models that Transform Health Systems
10. Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
11. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014  Endo ... ENDP ) (TSX: ENL), and BioDelivery Sciences ... that they have submitted a New Drug Application (NDA) ... and Drug Administration (FDA).  Buprenorphine HCl Buccal Film is ... to require daily, around-the-clock, long-term opioid treatment and for ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has ... Glucose Market" report to their offering. ... insight focuses on the developments in the self-monitoring blood ... . Reimbursement analysis and the effects of competitive bidding ... 73 SMBG meters have been performed, based on the ...
(Date:12/22/2014)... , Dec. 22, 2014 Swedish Orphan ... today announced that the Committee for Medicinal Products for ... has adopted a positive opinion for the use of ... men with Peyronie,s disease with a palpable plaque and ... start of therapy. The use of Xiapex ...
Breaking Medicine Technology:Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5US Self-monitoring Blood Glucose Market 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... Inc. (NASDAQ: SSRX ) ("3SBio" or "the ... developing, manufacturing and marketing biopharmaceutical products, today announced that ... after the NASDAQ stock market closes on Monday, August ... Following the earnings announcement, 3SBio,s senior management will host ...
... July 21, 2011 Dr. Kaveh Kardooni ... specializing in Neuroradiology. Dr. Kardooni graduated from ... of science in biology. He received his medical degree ... Dr. Kardooni completed his diagnostic radiology residency in 2009 ...
Cached Medicine Technology:3SBio Inc. Schedules Unaudited Second Quarter 2011 Results 2Desert Radiologists Welcomes Dr. Kaveh Kardooni 2
(Date:12/25/2014)... 26, 2014 The microscopy market ... 7.2% to reach $5,756.0 million by 2019. Optical ... market. The electron microscopes product segment is expected ... period. , Rising focus on nanotechnology, technological advancements, ... the microscopy market. , Get Full Copy of ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... and Market Analysis to 2023” focuses on the ... commercial opportunities in the colorectal cancer market. Stivarga ... treatment of colon or rectal cancer. Boehringer Ingelheim ... inhibitor, for the treatment of refractory CRC in ...
(Date:12/25/2014)... “Every three months the trends for evening ... dress will be one of the hottest styles in the ... Today, the company releases 26 A-line sweetheart evening dresses, and ... , “We are trying our best to help a ... designs. Along with affordable prices, we provide discounted delivery costs ...
(Date:12/25/2014)... December 25, 2014 The short film “Color ... created in honor of a true 9/11 hero, Welles Remy ... festivals including the 24 hours of Nuremberg International Short Film ... , Actress, screenwriter and director Luciana Lagana ... film together with her husband, Gregory Graham - ...
(Date:12/25/2014)... 2014 Helen Harris’ RP (Retinitis Pigmentosa) ... California after an 8 year battle with breast cancer. ... evening in her home in Woodland Hills California after ... , As the founder and volunteer ... pioneered and championed many of today's greatest breakthroughs in ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... Feb. 9 (HealthDay News) -- A growing number of Americans ... social networking sites rather than friends, a new survey ... information from social media such as Facebook and Twitter, a ... number of patients who sought information from friends fell from ...
... Moffitt Cancer Center in Tampa, Fla., have discovered that ... roles in tobacco-related non-small cell lung cancers. Tobacco carcinogens ... The study was published in a recent issue ... identified oconogene, a gene linked to cancer," said study ...
... certain cancer cells may exhibit greater flexibility than normal ... tumor growth. Now computer simulations developed by Boston University ... the University of Texas at Austin appear to support ... cells that they,ve created indicates that the softening of ...
... 9, 2012) In a study to be presented ... The Pregnancy Meeting , in Dallas, Texas, researchers will ... delivery via cesarean section appear to know little about ... second cesarean or trial of labor to attempt a ...
... Fla. and ORLANDO, Fla. Moffitt Cancer Center, ... announced they will collaborate on the creation of ... The partnership will conduct collaborative research to accelerate ... of cancer and metabolic diseases, including obesity, diabetes ...
... SAN FRANCISCO There is growing evidence that supports an association ... the thigh bone, typically without trauma and the use ... fracture incidence caused by osteoporosis. While the risk for suffering ... small just 1 in 1,000 patients after six years ...
Cached Medicine News:Health News:More Patients Seek Plastic Surgery Advice From Facebook, Twitter 2Health News:Researchers find important 'target' playing role in tobacco-related lung cancers 2Health News:Boston University research suggests new pathways for cancer progression 2Health News:Study finds pregnant women with prior cesarean choose the delivery method preferred by their doctor 2Health News:Moffitt, Sanford-Burnham and Florida Hospital create Personalized Medicine Partnership of Florida 2Health News:Moffitt, Sanford-Burnham and Florida Hospital create Personalized Medicine Partnership of Florida 3Health News:Halting bone-building osteoporosis drug use cuts risk for additional atypical femur fracture in half 2
Compact networked patient monitors for flexible care....
... heritage in patient monitoring, IntelliVue has highly ... menu; built-in clinical support tools such as ... arrhythmia analysis; and many other powerful features., ... operates on a networked platform that can ...
... vital sign monitor. , ,Adult, pediatric, and neonatal. ... in patient care., ,Standard Functions: ,ECG - Respiration ... Multi-gas Sensor (HAL, ENF, ISO, DES, SEV, N ... ECG - FiO 2 - 2-Invasive Pressures - ...
... Welch Allyn Atlas monitor is a low-cost, ... IV anesthesia procedures, and surgery. The large ... that are visible from across the room. ... how to operate the monitor in just ...
Medicine Products: